Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | CES1 | P23141 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27779276 | 0.82 | HDAC4 (0.51) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL3711116 | 0.82 | SRC (0.58) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL29010063 | 0.82 | PGK1 (0.44) | KDM4E | |
| SCHEMBL29831294 | 0.80 | CES2 (0.66) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL4390797 | 0.80 | HDAC4 (0.53) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL29530737 | 0.80 | HDAC4 (0.53) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL11353282 | 0.80 | CES2 (0.66) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL3232636 | 0.80 | KYNU (0.51) | KDM4EPARP1 | |
| SCHEMBL9298252 | 0.80 | HDAC4 (0.53) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL287924 | 0.80 | CES2 (0.66) | HDAC4HDAC7HDAC5CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-4193399-A2 | ELECTRONIC DEVICE | Merck Patent GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3298639-B1 | FORMULATION CONTAINING AN ORGANIC SEMICONDUCTOR AND A METAL COMPLEX | MERCK PATENT GMBH (DE) | 2021-01-13 | — | — | EP | disclosed |
| CN-107667439-B | Formulations comprising organic semiconductors and metal complexes | 默克专利有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-10581001-B2 | Organic electronic component having a charge carrier generation layer and the use of a zinc complex as a P-type dopant in charge carrier generation layers | OSRAM OLED GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-10566550-B2 | Formulation containing an organic semiconductor and a metal complex | MERCK PATENT GMBH (DE) | 2020-02-18 | — | — | US | disclosed |
| US-10256422-B2 | Organic electronic component, use of a zinc complex as a p-dopant for organic electronic matrix materials | OSRAM OLED GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20190074453-A1 | FORMULATION CONTAINING AN ORGANIC SEMICONDUCTOR AND A METAL COMPLEX | MERCK PATENT GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20180277778-A1 | ORGANIC ELECTRONIC COMPONENT HAVING A CHARGE CARRIER GENERATION LAYER AND THE USE OF A ZINC COMPLEX AS A P-TYPE DOPANT IN CHARGE CARRIER GENERATION LAYERS | OSRAM OLED GMBH (DE) | 2018-09-27 | — | — | US | disclosed |
| EP-3298639-A1 | FORMULATION CONTAINING AN ORGANIC SEMICONDUCTOR AND A METAL COMPLEX | Merck Patent GmbH (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| CN-102917588-B | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-08 | — | — | CN | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
| EP-1881988-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006122200-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10581001-B2 | Organic electronic component having a charge carrier generation layer and the use of a zinc complex as a P-type dopant in charge carrier generation layers | SCO2, NCOA4, NR4A2 | HDAC4 594/4885HDAC7 3333/4885HDAC5 2517/4885 |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | HDAC4 1146/4885HDAC7 2119/4885HDAC5 1905/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | HDAC4 3077/4885HDAC7 4061/4885HDAC5 2468/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | HDAC4 3077/4885HDAC7 4061/4885HDAC5 2468/4885 |
| US-20180277778-A1 | ORGANIC ELECTRONIC COMPONENT HAVING A CHARGE CARRIER GENERATION LAYER AND THE USE OF A ZINC COMPLEX AS A P-TYPE DOPANT IN CHARGE CARRIER GENERATION LAYERS | SCO2, NCOA4, NR4A2 | HDAC4 594/4885HDAC7 3333/4885HDAC5 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.